Emerging therapies for MASLD and their impact on plasma lipids

Madison Nguyen, Amon Asgharpour, Dave L. Dixon, Arun J. Sanyal, Anurag Mehta

Research output: Contribution to journalArticlepeer-review


Metabolic-dysfunction associated steatotic liver disease (MASLD) affects 1 out of every 3 individuals in the adult population and the disease prevalence is predicted to increase worldwide. Patients with MASLD are also burdened by cardiovascular disease, which is the leading cause of mortality in this population. Complex metabolic derangements such as insulin resistance and atherogenic dyslipidemia affect patients with MASLD. In patients with MASLD, treatment such as pharmacotherapy may be best directed towards improving the adverse concomitant metabolic disorders associated with MASLD, particularly the ones that may contribute to MASLD. Herein, we discuss conventional therapies that target cardiometabolic risk factors which have the potential to improve hepatic injury, and summarize emerging therapies that target hepatic receptors, fibrosis, and fatty acid oxidation in patients with MASLD. Given the relationship between hepatic injury which leads to MASLD, insulin resistance, and ultimately atherogenic dyslipidemia our review uniquely delves into the effects of conventional and emerging therapies for MASLD on plasma lipid parameters.

Original languageEnglish
Article number100638
JournalAmerican Journal of Preventive Cardiology
StatePublished - Mar 2024
Externally publishedYes


  • Atherosclerosis
  • Cardiometabolic disease
  • Dyslipidemia
  • Metabolic-dysfunction associated steatohepatitis
  • Metabolic-dysfunction associated steatotic liver disease


Dive into the research topics of 'Emerging therapies for MASLD and their impact on plasma lipids'. Together they form a unique fingerprint.

Cite this